This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sarris, A. H. Articles by Cabanillas, F. Search for Related Content PubMed PubMed Citation Articles by Sarris, A. H. Articles by Cabanillas, F. Social Bookmarking                            What's this?

Trimetrexate in Relapsed T-Cell Lymphoma With Skin Involvement

From the Departments of Lymphoma and Myeloma, Dermatology, and Hematopathology and Divisions of Pharmacy and Radiology, University of Texas M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Andreas H. Sarris, MD, PhD, Hygeia Hospital, Evythrou Stavrou 4, 15123 Marousi, Greece; email: a.sarris{at}hygeia.gr

PURPOSE: Methotrexate (MTX) is active against lymphomas, but transport or polyglutamylation mutations confer MTX resistance. Because trimetrexate (TMTX) enters cells by passive diffusion and is not polyglutamylated, its activity in relapsed T-cell lymphoma was investigated.

PATIENTS AND METHODS: Eligible patients had histologically confirmed relapsed T-cell lymphoma involving the skin, had received more than one previous regimen, were older than 16 years, had normal organ function, and had no CNS disease or serious infections, including human immunodeficiency virus. TMTX (200 mg/m²) was given intravenously every 14 days without topical or systemic corticosteroids. Patients who responded received up to 12 doses.

RESULTS: Twenty patients were assessable for response. Median age was 59 years (range, 45 to 87 years); 13 patients were men. Three patients had anaplastic large-cell lymphoma, 15 had mycosis fungoides or Sézary syndrome (14 with large-cell transformation), and two had peripheral T-cell lymphoma. Serum lactate dehydrogenase was high in 35%, and beta-2 microglobulin was more than 3.0 mg/L in 35% of patients. The median number of previous regimens was three (range, two to 15) and included MTX in five patients. Disease was refractory to the regimen immediately preceding TMTX in 85% of patients. Responses were complete in one and partial in eight patients (overall response rate, 45%). Two of five patients previously treated with MTX responded. Grade 3 or 4 mucositis was observed after 4%, infection after 3%, neutropenic fever after 6%, neutrophils less than 100/µL after 4%, and platelets less than 10,000/µL after 3% of TMTX doses.

CONCLUSION: TMTX is active with acceptable toxicity in this population and merits further investigation.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Jacobsen Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type Oncologist, July 1, 2006; 11(7): 831 - 840. [Abstract] [Full Text] [PDF]